Companies › Amgen
32 active drug programs in 277 registered trials: 113 Phase 2, 73 Phase 3, 62 Phase 1, 29 Phase 4; Oncology, Metabolic and endocrine, Other, Genitourinary; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Denosumab Tumor necrosis factor ligand superfamily member 11 inhibitor | TNFSF11 | Phase 4 | Osteoporosis; Glucocorticoid-induced Osteoporosis; Giant Cell Tumor of Bone; Osteoporosis, Postmenopausal … | Jan 2027 |
| Inebilizumab B-lymphocyte antigen CD19 binding agent | CD19 | Phase 4 | Neuromyelitis Optica Spectrum Disorder; IgG4 Related Disease; Myasthenia Gravis; Autoimmune Hepatitis … | Apr 2027 |
| Evolocumab Subtilisin/kexin type 9 inhibitor | PCSK9 | Phase 4 | Cardiovascular Disease | May 2027 |
| Avacopan C5a anaphylatoxin chemotactic receptor antagonist | C5AR1 | Phase 4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis; Vasculitis; ANCA Associated Vasculitis (AAV); Granulomatosis With Polyangiitis | Jul 2027 |
| Maridebart cafraglutide (AMG 133) GLP-1 receptor agonist and GIP receptor agonist (dual GLP-1/GIP receptor agonist) | GLP1R, GIPR | Phase 3 | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight; Obesity; Obesity Disease; Obstructive Sleep Apnea … | Nov 2026 |
| Teprotumumab Insulin-like growth factor I receptor antagonist | IGF1R | Phase 3 | Thyroid Eye Disease | Nov 2026 |
| Erenumab Calcitonin gene-related peptide type 1 receptor antagonist | CALCRL | Phase 3 | Migraine; Posttraumatic Headache; Schwannomatosis | Nov 2026 |
| ABP 234 PD-1 inhibitor (pembrolizumab biosimilar) | PDCD1 | Phase 3 | Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC); Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer | Dec 2026 |
| Dazodalibep CD40 ligand antagonist | CD40LG | Phase 3 | Sjögren's Syndrome (SS); Sjögren's Syndrome; Lupus Nephritis | Dec 2026 |
| Sotorasib GTPase KRas inhibitor | KRAS | Phase 3 | Non-Small Cell Lung Cancer (NSCLC); Metastatic Colorectal Cancer; Advanced Solid Tumors; Lung Adenocarcinoma … | Dec 2026 |
| Romosozumab Sclerostin inhibitor | SOST | Phase 3 | Osteogenesis Imperfecta; Healthy Participants; Osteoporosis; Postmenopausal Osteoporosis … | Jan 2027 |
| Xaluritamig (AMG 509) | – | Phase 3 | Metastatic Castration-resistant Prostate Cancer; Prostate Cancer; Metastatic Hormone-sensitive Prostate Cancer (mHSPC); Ewing Sarcoma … | Feb 2027 |
| Romiplostim Thrombopoietin receptor agonist | MPL | Phase 3 | Chemotherapy-induced Thrombocytopenia; Primary Immune Thrombocytopenia; CTIT: Cancer Therapy Induced Thrombocytopenia; Solid Tumors … | Feb 2027 |
| ABP 692 Anti-CD20 monoclonal antibody | MS4A1 | Phase 3 | Relapsing-remitting Multiple Sclerosis (RRMS) | Apr 2027 |
| Tarlatamab T cell surface glycoprotein CD3 binding agent; Delta-like protein 3 binding agent | CD3E, CD3G, CD3D, DLL3 | Phase 3 | Small Cell Lung Cancer; Small Cell Lung Cancer (SCLC); Small-cell Lung Cancer; Extensive-Stage Small-Cell Lung Cancer … | Apr 2027 |
| Etelcalcetide Calcium sensing receptor agonist | CASR | Phase 3 | Secondary Hyperparathyroidism | Jun 2027 |
| ABP 938 Anti-VEGF monoclonal antibody | VEGFA | Phase 3 | Neovascular Age-related Macular Degeneration | Jul 2027 |
| Blinatumomab T cell surface glycoprotein CD3 cross-linking agent; B-lymphocyte antigen CD19 cross-linking agent | CD3E, CD3G, CD3D, CD19 | Phase 3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL); B Precursor Acute Lymphoblastic Leukemia; Systemic Lupus Erythematosus; B Cell Precursor Acute Lymphoblastic Leukemia … | Oct 2027 |
| ABP 206 PD-L1 inhibitor | CD274 | Phase 3 | Melanoma | Jan 2028 |
| Apremilast Phosphodiesterase 4 inhibitor | PDE4A, PDE4D, PDE4B, PDE4C | Phase 3 | Plaque Psoriasis; Active Juvenile Psoriatic Arthritis; Behçet Disease; Behçet's Disease … | Mar 2028 |
| Olpasiran LPA mRNA rnai inhibitor | LPA | Phase 3 | Atherosclerotic Cardiovascular Disease; Cardiovascular Disease | Mar 2028 |
| Pegloticase Recombinant uricase enzyme that catalyzes degradation of uric acid | PTEN | Phase 3 | Uncontrolled Gout | Jun 2028 |
| Panitumumab Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 3 | Metastatic Colorectal Cancer; Advanced Solid Tumors; Colorectal Cancer Stage IV; Colorectal Neoplasms … | Jul 2028 |
| anvumetostat PRMT5 inhibitor in MTAP-deleted tumors | PRMT5 | Phase 2 | MTAP-deleted NSCLC; Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers; Advanced MTAP-null Solid Tumors; Thoracic Tumors | Nov 2026 |
| AMG 732 Insulin Growth Factor-1 Receptor (IGF-1R) pathway inhibitor via IGSF8 binding | IGSF8 | Phase 2 | Thyroid Eye Disease | Jan 2027 |
| RMC-4630 KRAS inhibitor (CoA-alkynes) | – | Phase 1 | Advanced Solid Tumors | Dec 2026 |
| GnRH Antagonist Gonadotropin-releasing hormone antagonist | GNRHR | Phase 1 | Prostate Cancer; Atypical Endometrial Hyperplasia; Endometrial Neoplasms | Feb 2027 |
| AMG 691 Unclear mechanism | – | Phase 1 | Healthy Participants; Asthma | Mar 2027 |
| AMG 127 | – | Phase 1 | Diabetes Mellitus, Type 2 | Oct 2027 |
| AMG 509 PSCA-directed chimeric costimulatory receptor T cell therapy | PSCA | Phase 1 | Extensive Stage Small Cell Lung Cancer; Prostate Cancer; Small Cell Lung Cancer | Mar 2028 |
| AMG 410 KRAS G12C inhibitor | KRAS | Phase 1 | KRAS Altered Advanced or Metastatic Solid Tumors | Apr 2028 |
| AMG 436 | – | Phase 1 | Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR) | Jan 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03623633 | Denosumab | Phase 4 | Osteoporosis, Postmenopausal | Metabolic and endocrine | Feb 2023 |
| NCT05212337 | Denosumab | Phase 2 | Infertility, Male | Genitourinary | Oct 2024 |
| NCT04549207 | Denosumab | Phase 4 | Breast Cancer | Oncology | Apr 2025 |
| NCT02790515 | Blinatumomab | Phase 2 | Acute Lymphoblastic Leukemia (ALL) | Oncology | Jul 2025 |
| NCT06509984 | Apremilast | Phase 2 | Epidermolysis Bullosa Simplex | Other | Oct 2025 |
| NCT03512405 | Blinatumomab | Phase 1 | CD19 Positive | Oncology | Nov 2025 |
| NCT05565560 | Apremilast | Phase 3 | Plaque Psoriasis | Immunology | Nov 2025 |
| NCT05096195 | Denosumab | Phase 4 | Kidney Diseases | Genitourinary | Dec 2025 |
| NCT06759636 | Romiplostim | Phase 3 | CTIT: Cancer Therapy Induced Thrombocytopenia | Oncology | Apr 2026 |
| NCT05182385 | Blinatumomab | Phase 1 | ALL, Recurrent, Adult | Oncology | Apr 2026 |
| NCT07283887 | Romosozumab | Phase 4 | Osteoporosis | Metabolic and endocrine | Jul 2026 |
| NCT07063225 | Romiplostim | Phase 2 | Chemotherapy-induced Thrombocytopenia | Hematology | Aug 2026 |
| NCT06324435 | Apremilast | Phase 1 | Alcohol Use Disorder | Psychiatry | Aug 2026 |
| NCT07043894 | Romiplostim | Phase 2 | Solid Tumors | Oncology | Sep 2026 |
| NCT05325593 | Romiplostim | Phase 3 | Primary Immune Thrombocytopenia | Hematology | Oct 2026 |
| NCT02877303 | Blinatumomab | Phase 2 | B Acute Lymphoblastic Leukemia | Oncology | Nov 2026 |
| NCT06660173 | Maridebart cafraglutide (AMG 133) | Phase 2 | Type 2 Diabetes Mellitus (T2DM) | Metabolic and endocrine | Nov 2026 |
| NCT06248619 | Teprotumumab | Phase 3 | Thyroid Eye Disease | Ophthalmology | Nov 2026 |
| NCT07160257 | Maridebart cafraglutide (AMG 133) | Phase 1 | Type 2 Diabetes Mellitus | Metabolic and endocrine | Nov 2026 |
| NCT03836040 | Erenumab | Phase 3 | Migraine | Neurology | Nov 2026 |
| NCT07523711 | Maridebart cafraglutide (AMG 133) | Phase 1 | Overweight | Metabolic and endocrine | Nov 2026 |
| NCT03755193 | Denosumab | Phase 2 | Osteoporosis | Metabolic and endocrine | Nov 2026 |
| NCT06249282 | Sotorasib | Phase 1 | Advanced Lung Non-Small Cell Carcinoma | Oncology | Nov 2026 |
| NCT06593522 | anvumetostat | Phase 2 | MTAP-deleted NSCLC | Oncology | Nov 2026 |
| NCT06360354 | anvumetostat | Phase 1 | Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers | Gastroenterology | Nov 2026 |
| NCT05094336 | anvumetostat | Phase 1 | Advanced MTAP-null Solid Tumors | Oncology | Nov 2026 |
| NCT06333951 | anvumetostat | Phase 1 | Thoracic Tumors | Oncology | Nov 2026 |
| NCT06749886 | Denosumab | Phase 2 | Lung Cancer | Oncology | Nov 2026 |
| NCT03983993 | Panitumumab | Phase 2 | Advanced Microsatellite Stable Colorectal Carcinoma | Oncology | Dec 2026 |
| NCT06387121 | Blinatumomab | Phase 2 | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Oncology | Dec 2026 |
| NCT06693791 | Romiplostim | Phase 2 | Platelet Recovery After Umbilical Cord Blood Transplantation | Other | Dec 2026 |
| NCT06430866 | ABP 234 | Phase 3 | Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC) | Oncology | Dec 2026 |
| NCT04227314 | Apremilast | Phase 3 | Recurrent Aphtous Stomatitis | Gastroenterology | Dec 2026 |
| NCT03541083 | Blinatumomab | Phase 2 | ALL, Adult | Oncology | Dec 2026 |
| NCT04185883 | Sotorasib | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2026 |
| NCT06245408 | Dazodalibep | Phase 3 | Sjögren's Syndrome (SS) | Immunology | Dec 2026 |
| NCT04185883 | RMC-4630 | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2026 |
| NCT03114865 | Blinatumomab | Phase 1 | Acute Lymphoblastic Leukemia | Oncology | Dec 2026 |
| NCT04625647 | Sotorasib | Phase 2 | Lung Adenocarcinoma | Oncology | Dec 2026 |
| NCT06339775 | Blinatumomab | Phase 4 | Acute B-cell Lymphoblastic Leukemia | Oncology | Dec 2026 |
| NCT06250959 | Blinatumomab | Phase 2 | ALL, Adult | Oncology | Dec 2026 |
| NCT06401044 | AMG 732 | Phase 1 | Thyroid Eye Disease | Ophthalmology | Jan 2027 |
| NCT07811999 | Romosozumab | Phase 1 | Healthy Participants | Other | Jan 2027 |
| NCT06886074 | Blinatumomab | Phase 2 | Acute Lymphoblastic Leukemia | Oncology | Jan 2027 |
| NCT06858878 | Maridebart cafraglutide (AMG 133) | Phase 3 | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight | Metabolic and endocrine | Jan 2027 |
| NCT06858839 | Maridebart cafraglutide (AMG 133) | Phase 3 | Obesity | Metabolic and endocrine | Jan 2027 |
| NCT06332014 | Denosumab | Phase 4 | Osteoporosis | Metabolic and endocrine | Jan 2027 |
| NCT03087071 | Panitumumab | Phase 2 | EGFR NP_005219.2:p.S492R | Oncology | Jan 2027 |
| NCT07325266 | Apremilast | Phase 2 | Alcohol Use Disorder | Psychiatry | Jan 2027 |
| NCT06898983 | Romiplostim | Phase 2 | Cancer Treatment-induced Thrombocytopenia (CTIT) | Oncology | Jan 2027 |
| NCT03739814 | Blinatumomab | Phase 2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Oncology | Feb 2027 |
| NCT05519579 | Blinatumomab | Phase 2 | Acute Lymphoblastic Leukemia | Oncology | Feb 2027 |
| NCT07854561 | Romiplostim | Phase 2 | Anemia Associated With Chronic Kidney Disease | Genitourinary | Feb 2027 |
| NCT06613100 | Xaluritamig (AMG 509) | Phase 1 | Prostate Cancer | Oncology | Feb 2027 |
| NCT06613100 | GnRH Antagonist | Phase 1 | Prostate Cancer | Oncology | Feb 2027 |
| NCT03937154 | Romiplostim | Phase 3 | Chemotherapy-induced Thrombocytopenia | Oncology | Feb 2027 |
| NCT02003222 | Blinatumomab | Phase 3 | Acute Lymphoblastic Leukemia | Oncology | Feb 2027 |
| NCT05747625 | Panitumumab | Phase 1 | Head and Neck Squamous Cell Carcinoma | Oncology | Feb 2027 |
| NCT03147612 | Blinatumomab | Phase 2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Oncology | Feb 2027 |
| NCT04608630 | Denosumab | Phase 2 | Critical Illness | Metabolic and endocrine | Feb 2027 |
The 60 nearest readouts of 277 trials; the rest in the app.
Cash of $13.2bn on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.